Bayer and Exscientia Collaborate to Leverage the Potential of Artificial Intelligence in Cardiovascular and Oncology Drug Discovery
Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary AI drug discovery platform and drug design know-how with Bayer's data and drug discovery capabilities.
At CES 2020, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its expansion of personalized consumer health solutions that help shape the industry of consumer health. With the expansion of the collaboration with Delta Dental of California to improve oral care outcomes, the introduction of Baby+ to support new parents and the SmartSleep suite of solutions, Philips is addressing people’s individual needs and empowering them to make healthier choices.
Today it's commonplace, but at the time it was a medical-technical revolution - the discovery of X-rays by Wilhelm Conrad Röntgen 125 years ago in Würzburg. His discovery on November 8, 1895 heralded a new era in medicine that provided previously unknown insights into the human body.
Gloucestershire Hospitals NHS Foundation Trust has gone live with the first elements of its Allscripts Sunrise electronic patient record just five months after signing a contract with the company.
Is it possible to screen thousands of people for tuberculosis using artificial intelligence in a country where internet barely exists? It is with CAD4TB. As of October, this innovative software is used to screen people for TB in even the remotest areas of Eritrea. It has been developed by Dutch company Thirona in collaboration with the also Dutch Delft Imaging Systems.